Karyopharm Therapeutics Inc. (KPTI)
NASDAQ: KPTI · Real-Time Price · USD
1.870
-0.070 (-3.61%)
Aug 28, 2026, 4:00 PM EDT - Market closed
Karyopharm Therapeutics Revenue
Karyopharm Therapeutics had revenue of $33.43M in the quarter ending June 30, 2026, a decrease of -11.86%. This brings the company's revenue in the last twelve months to $146.62M, up 6.81% year-over-year. In the year 2025, Karyopharm Therapeutics had annual revenue of $146.07M with 0.57% growth.
Revenue (ttm)
$146.62M
Revenue Growth
+6.81%
P/S Ratio
0.29
Revenue / Employee
$643,075
Employees
228
Market Cap
42.41M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 146.07M | 830.00K | 0.57% |
| Dec 31, 2024 | 145.24M | -796.00K | -0.55% |
| Dec 31, 2023 | 146.03M | -11.04M | -7.03% |
| Dec 31, 2022 | 157.07M | -52.75M | -25.14% |
| Dec 31, 2021 | 209.82M | 101.73M | 94.12% |
| Dec 31, 2020 | 108.09M | 67.19M | 164.31% |
| Dec 31, 2019 | 40.89M | 10.56M | 34.80% |
| Dec 31, 2018 | 30.34M | 28.73M | 1,790.09% |
| Dec 31, 2017 | 1.61M | 1.45M | 942.21% |
| Dec 31, 2016 | 154.00K | -96.00K | -38.40% |
| Dec 31, 2015 | 250.00K | 21.00K | 9.17% |
| Dec 31, 2014 | 229.00K | -158.00K | -40.83% |
| Dec 31, 2013 | 387.00K | -247.00K | -38.96% |
| Dec 31, 2012 | 634.00K | 482.00K | 317.11% |
| Dec 31, 2011 | 152.00K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Aligos Therapeutics | 31.52M |
| Werewolf Therapeutics | 21.00M |
| Veru Inc. | 16.89M |
| Metagenomi Therapeutics | 13.56M |
| Mereo BioPharma Group | 500.00K |
| CervoMed | 331.30K |
| Impact BioMedical | 35.00K |
KPTI News
- 11 days ago - Karyopharm reports Q2 EPS ($2.32) vs. ($4.32) last year - TheFly
- 15 days ago - Karyopharm Therapeutics Earnings Call Transcript: Q2 2026 - Transcripts
- 15 days ago - Karyopharm Therapeutics Earnings release: Q2 2026 - Filings
- 15 days ago - Karyopharm Therapeutics Quarterly report: Q2 2026 - Filings
- 15 days ago - Karyopharm Therapeutics Slides: Q2 2026 - Filings
- 15 days ago - Karyopharm Reports Second Quarter 2026 Financial Results and Highlights Continued Progress Toward Myelofibrosis sNDA Submission - PRNewsWire
- 18 days ago - Karyopharm to Report Second Quarter 2026 Financial Results on August 13, 2026 - PRNewsWire
- 25 days ago - Karyopharm Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - PRNewsWire